All About Noah Medical's Galaxy System

All About Noah Medical's Galaxy System

Noah Medical has emerged as a trailblazer with its Galaxy System™. This robotic platform is poised to redefine the landscape of bronchoscopy procedures. Their collective mission is clear: to empower physicians with earlier diagnoses and an unprecedented level of confidence in bronchoscopy procedures. 

Let's take a dive into this remarkable advancement and explore how it is revolutionizing the field of medical robotics.

The Galaxy System

What distinguishes the Galaxy System™ is its ability to surmount the intricate challenge of CT-to-body divergence. This technological prowess significantly elevates diagnostic accuracy, but what precisely is CT-to-body divergence, and why is it a stumbling block in bronchoscopy?

CT-to-Body Divergence

CT scans, known as computed tomography, play a pivotal role in medical imaging by creating detailed cross-sectional images of the human body. These scans offer valuable insights into the location, size, and characteristics of lung lesions or abnormalities.

However, during bronchoscopy, a disconnect often arises between the CT scan's image and the actual location of a lesion or target within the patient's body. This divergence is attributable to variations in the patient's body position and breathing patterns during the procedure, in contrast to when the CT scan was taken.

CT-to-body divergence presents a hurdle for bronchoscopy practitioners, as it can lead to misalignment between the intended path and the actual lesion location. Such misalignment can result in missed targets, diminished diagnostic accuracy, and heightened procedural risks.

The Galaxy System's TiLT+ Technology™ emerges as a game-changing solution by providing real-time updates and guidance during the procedure. This real-time feedback empowers physicians to rectify CT-to-body divergence, ensuring precise navigation to the intended target within the lung.

TiLT+ Reconstruction

The Galaxy System, equipped with TiLT+ Technology, introduces the groundbreaking concept of TiLT+ Reconstruction. This innovation redefines the visualization and localization of the biopsy tool within the lesion. By harnessing a facility's C-arm, this technology significantly enhances diagnostic accuracy, allowing physicians to navigate and perform biopsies with confidence.

Augmented Fluoroscopy

Losing sight of the lesion is not an option in bronchoscopy, and the Galaxy System ensures just that. In fact, the Galaxy is the only solution offering Augmented Fluoroscopy, a feature that overlays a graphic representation of both the tool and the lesion. This real-time visual aid enables physicians to make on-the-fly adjustments for precise tool deployment, guaranteeing that each biopsy is flawlessly on target.

True Targeting™

In the pivotal moments of a procedure, True Targeting™ emerges as the guiding star. The Galaxy System presents a targeting system that hinges on real-time lesion updates, assuring pinpoint accuracy during the procedure's most critical phases.

Strikepoint™

Precision becomes quantifiable with the Galaxy System's Strikepoint™. This feature calculates the distance between the tool's tip and the center of the lesion, offering a tangible measure of tool-in-lesion confirmation. With this data at hand, physicians can rest assured that their biopsy tool is precisely where it should be.

Proven Excellence: The MATCH Study

The Galaxy System has already demonstrated its prowess in the field through the landmark MATCH Study. This study, showcased successful digital TOMO-confirmed Tool-in-Lesion (TIL) success in 95% (19/20) of lesions and Tool-in-Lesion (TTL) in 5% (1/20) as confirmed by CBCT. Furthermore, it achieved a 100% diagnostic yield as confirmed by intralesional pigment acquisition (the process of obtaining or capturing pigmented material or substances from within a lesion or abnormal tissue area during a medical procedure). While additional clinical trials are warranted, these results underscore the Galaxy Robotic System's outstanding performance.

The FRONTIER Study

The FRONTIER Study, unveiled at the AABIP 2023 Abstract Presentation, marks the next frontier. The study set out to evaluate the safety and feasibility of leveraging the Galaxy System for bronchoscopically biopsying small peripheral pulmonary nodules ranging from 1 to 3 cm in size.

The results showed: 100% successful navigation, 100% demonstrated tool-in-lesion confirmation, and an estimated diagnostic yield ranging from 89.5% to 94.7%. These findings not only reaffirm the safety and feasibility of the Galaxy Robotic System but also underscore its tool-in-lesion precision and diagnostic prowess within the study's patient participants.

Efficiency Reimagined

Yet, the success of the Galaxy System doesn't solely hinge on precision; it's also about efficiency. The system has been designed with procedural efficiency in mind. Here's how it streamlines the bronchoscopy process:

1. Single-Use Bronchoscope and Accessories

The Galaxy System introduces a single-use bronchoscope and accessories, minimizing the risk of cross-contamination and expediting turnaround times. This means no more time-consuming scope reprocessing, allowing medical professionals to focus on what matters most—the patient.

2. Space-Saving Design

In crowded bronchoscopy suites and operating rooms where space is often at a premium, the Galaxy System shines. Its purposeful design provides a compact footprint and a single cart design, enhancing maneuverability and saving valuable space. This efficient use of space contributes to a more organized and effective healthcare environment.

3. User-Friendly Setup and Teardown

The Galaxy System doesn't forget about the healthcare support staff. Its simple setup and teardown process make life easier for everyone involved, ultimately boosting the overall efficiency of lung biopsy procedures. This user-friendly approach fosters seamless coordination among the medical team, ensuring that procedures run smoothly and swiftly.

The Galactic Future of Medical Diagnostics

The Galaxy System by Noah Medical stands as a beacon of progress. With its groundbreaking TiLT+ Technology™ and the remarkable results of both The MATCH Study and The FRONTIER Study, it offers a level of precision, confidence, and efficiency that was once unimaginable.

The Galaxy System also holds immense promise in the battle against lung cancer. Lung cancer, one of the deadliest forms of cancer worldwide, often demands precise and early diagnosis for effective treatment. With its advanced features, including real-time navigation, TiLT+ Technology™, and Augmented Fluoroscopy, the Galaxy System empowers medical professionals to navigate the intricate landscape of the respiratory system with unparalleled precision.

This level of accuracy is particularly crucial when dealing with lung cancer, as early detection and targeted biopsies are paramount to survival. By enabling physicians to confidently locate and biopsy suspicious lesions, the Galaxy System plays a pivotal role in the timely diagnosis and subsequent management of lung cancer cases. The Galaxy System offers hope and optimism in the quest to improve patient outcomes and ultimately conquer lung cancer.

Source: Noah Medical

January 3, 2024
Tom Shrader
Tags:
Cancer
Robot
Robotic Surgery

Relevant Articles

R2 Surgical Joins Imagination Station's Girl Power Event to Inspire STEAM Careers
R2 Surgical Joins Imagination Station's Girl Power Event to Inspire STEAM Careers
February 9, 2024

R2 Surgical Joins Imagination Station's Girl Power Event to Inspire STEAM Careers

TOLEDO, OH - We are thrilled to announce R2 Surgical's participation in Imagination Station Toledo’s...
R2 Surgical's Founder to Speak About Accessibility and Sustainability in Surgical Robotics at Upcoming Webinar
R2 Surgical's Founder to Speak About Accessibility and Sustainability in Surgical Robotics at Upcoming Webinar
February 7, 2024

R2 Surgical's Founder to Speak About Accessibility and Sustainability in Surgical Robotics at Upcoming Webinar

TOLEDO, OH - Tom Shrader, Founder and President of R2 Surgical, will present at the...
Cornell University Performs First Live Animal Robotic Gastropexy With Assistance From R2 Surgical
Cornell University Performs First Live Animal Robotic Gastropexy With Assistance From R2 Surgical
January 10, 2024

Cornell University Performs First Live Animal Robotic Gastropexy With Assistance From R2 Surgical

Ithaca, NY - R2 Surgical, a global supplier of surgical robotic systems and accessories, proudly...
Robotic GERD Surgery
Robotic GERD Surgery
January 8, 2024

Robotic GERD Surgery

Gastroesophageal Reflux Disease (GERD) is a common gastrointestinal disorder affecting millions of people worldwide. Characterized...

Subscribe To Our Newsletter

Sign Up Now